ImmunoCellular CEO resigns

WORKFLOW SOLUTIONS
PRODUCTS
See More S&P Global Solutions
CONTENT
PODCASTS
SEE ALL EPISODES
SECTOR-SPECIFIC INSIGHTS
More ways we can help
NEWS & RESEARCH TOPICS
See More
Featured Events
Webinar Accelerated IR: 2024 Strategy – Planning, Executing & Measuring Success for the Year Ahead
- 10/04/2023
- Live, Online
- 11:00 am - 12:00 pm EDT
WebinarAdvancing LGBTQ+ Inclusion in Global Organizations: Insights from ESG Filings
- 10/05/2023
- Live, Online
- 11:00 am - 12:00 pm EDT
In PersonHosting and Cloud Transformation Summit 2023
- 10/10/2023
- SECOND, NYC, 849 6th Ave, New York
- 7:30am – 6:30pm EDT
PLATFORMS
OTHER PRODUCTS
- Research Online
- 451 Research
See All Product Logins

In This List

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise

Blog

Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises

Blog

Essential IR Insights Newsletter - Summer July-August 2023

Blog

Insight Weekly: Climate law faces hurdles; US borrowing surges; banks revise uninsured deposits

15 Dec, 2016 | 02:26

Author Asma Khan
Theme Healthcare & Pharmaceuticals

ImmunoCellular Therapeutics Ltd. CEO Andrew Gengos is resigning, though he will remain on the board.

The company appointed Anthony Gringeri to replace him.

Gringeri has been working at ImmunoCellular as senior vice president of strategic resources since August 2013.

The company said the change reflects its strategy to focus on the ICT-107 program, a dendritic-cell based immunotherapy that targets brain cancer stem cells.